Autosomal Dominant Sleep-Related Hyperkinetic Epilepsy (ADSHE)

Autosomal dominant sleep-related hypermotor (hyperkinetic) epilepsy (ADSHE; formerly ADNFLE) is an inherited epilepsy where brief, sudden, often repetitive motor seizures happen mainly during sleep. People may jerk, sit up, thrash, pedal their legs, or show stiff or twisted postures; events usually last under two minutes and can cluster through the night. Awareness can be partly or fully kept, and a scary “warning” feeling (aura) can occur just before the movements. Daytime seizures are less common. Most people start having seizures in childhood or the teen years, but it can start earlier or later. Doctors diagnose ADSHE from the story, sleep-related timing, video-EEG, and by ruling out other sleep problems. It runs in families and follows an autosomal dominant pattern (a change in one copy of a gene can be enough). NCBI+1

ADSHE is a rare type of focal epilepsy where brief, stereotyped motor seizures happen mostly during sleep. Seizures can look like sudden sitting up, thrashing, kicking, fencing-like postures, or rapid complex movements with grunting or shouting. Events usually last under two minutes, often cluster several times in one night, and may recur for years. Awareness can be partly or fully preserved, and many people recall an aura (a warning feeling) before the movement starts. Daytime seizures are less common. Age at first seizure ranges from infancy to adulthood. The condition follows an autosomal-dominant inheritance pattern with incomplete penetrance. Schn Health NSW+3NCBI+3PMC+3

In ADSHE, the seizure focus often lies in or near the frontal lobes, but seizures are defined more by the sleep-related hypermotor pattern than by a fixed lobe. Brain MRI is frequently normal, but some families have subtle focal cortical dysplasia. Interictal EEG can be normal; diagnosis relies on video-EEG polysomnography that captures the typical sleep seizures. The key clinical task is to distinguish ADSHE from parasomnias (disorders of arousal) that can look similar but usually last longer, vary more from event to event, and happen once or twice a night with confused awakening and no recall. PMC+2Schn Health NSW+2

Genetically, ADSHE is heterogeneous. Classic families carry pathogenic variants in genes for neuronal nicotinic acetylcholine receptor (nAChR) subunits (CHRNA4, CHRNB2, CHRNA2). Other families carry variants in KCNT1 (a sodium-activated potassium channel) or in GATOR1-complex genes (DEPDC5, NPRL2, NPRL3) that regulate the mTOR pathway. These genes explain only a proportion of affected families; many cases have no identified variant. Phenotypes can vary by gene (for example, KCNT1 cases often start earlier and have more comorbidities). ScienceDirect+3MedlinePlus+3Frontiers+3

---

Other names

Older and related names you may see include: autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), sleep-related hypermotor epilepsy (SHE), and familial sleep-related hypermotor epilepsy. Today, “SHE” is the umbrella clinical term, and “ADSHE” indicates the familial, autosomal-dominant form. Schn Health NSW+1

---

Types

Doctors think about ADSHE along two simple axes:

1. By cause
   • Genetic ADSHE: due to pathogenic variants (nAChR genes; KCNT1; GATOR1 genes). Penetrance is incomplete, so not every carrier has seizures. MedlinePlus+1
   • Genetic-structural ADSHE: a gene variant plus a subtle malformation like focal cortical dysplasia (often type II). International League Against Epilepsy
   • Unknown-cause ADSHE/SHE: clinical picture fits SHE/ADSHE but no gene or lesion is found. Schn Health NSW

2. By seizure pattern severity
   • Minor motor (paroxysmal arousals): brief startle-like events, abrupt arousal, simple movements. PMC
   • Intermediate hypermotor: more complex dystonic/tonic postures and rapid movements. PMC
   • Major hypermotor: dramatic thrashing, bicycling, ballistic movements, loud vocalization. PMC

---

Causes

1. CHRNA4 variants. Changes in the α4 nAChR subunit increase network excitability during sleep transitions, creating a seizure-prone state. MedlinePlus

2. CHRNB2 variants. β2 nAChR subunit mutations alter receptor expression and function, shifting cholinergic signaling during N2/N3 sleep and facilitating hypermotor seizures. NCBI

3. CHRNA2 variants. α2 nAChR subunit mutations are less common but recognized in autosomal-dominant SHE families. Frontiers

4. KCNT1 variants. Gain-of-function in a sodium-activated K+ channel perturbs neuronal firing; these families may have earlier onset and cognitive/behavioral issues. PubMed+1

5. DEPDC5 variants (GATOR1). Loss-of-function disinhibits mTOR signaling; some carriers have focal cortical dysplasia and sleep-related hypermotor seizures. MedlinePlus+1

6. NPRL2 variants (GATOR1). Similar mTOR pathway over-activity increases cortical excitability and seizure risk during sleep. MedlinePlus

7. NPRL3 variants (GATOR1). Same mechanism as above; each GATOR1 gene explains a small fraction of ADSHE families. MedlinePlus

8. CRH gene variants. Abnormal corticotropin-releasing hormone signaling can modulate arousal circuits and seizure thresholds at night. NCBI

9. CABP4 variants (rare reports). Calcium-binding protein 4 has been reported in some series of ADSHE; evidence is limited but growing. PubMed

10. Undetected focal cortical dysplasia. Subtle malformation can drive nocturnal focal seizures despite a “normal” MRI. International League Against Epilepsy

11. Other rare genes. Ongoing research shows additional candidate genes; cumulatively, known genes explain ~30% of families. ScienceDirect

12. Sleep instability. The NREM stage transitions (especially N2→N3) create windows where thalamo-cortical circuits are vulnerable to seizures. PMC

13. Cholinergic arousal modulation. Nicotinic receptor dysfunction can mis-time arousal bursts during sleep, triggering hypermotor patterns. NCBI

14. mTOR pathway over-activation. GATOR1 loss increases mTOR activity; hyperexcitable networks are more likely to seize during sleep. MedlinePlus

15. Family history (autosomal dominant). A first-degree relative with similar nocturnal events raises the likelihood of genetic ADSHE. NCBI

16. Incomplete penetrance and modifiers. Not all carriers seize; unknown modifiers (genetic or environmental) influence expression. International League Against Epilepsy

17. Early-life brain development factors. Even without a visible lesion, developmental circuit wiring may bias toward hypermotor seizures. PMC

18. KCNT1-related network dysrhythmia. Persistent channel over-activity can lock networks into a hyperexcitable state during sleep. Taylor & Francis Online

19. Covert structural-genetic overlap. Some “genetic” cases harbor micro-lesions below routine MRI resolution. International League Against Epilepsy

20. Unknown (idiopathic) mechanisms. Many people meet clinical criteria for SHE/ADSHE but no cause is found despite thorough testing. Schn Health NSW

---

Symptoms & signs

1. Repeated night-time attacks. Several events per night, sometimes many nights per week. PMC

2. Very short duration. Most events last seconds to under two minutes. NCBI

3. Stereotyped pattern. Each person’s events look very similar each time. PMC

4. Sudden arousal from sleep. People may sit up abruptly or appear “switched on.” PMC

5. Hypermotor movements. Thrashing, bicycling, jumping, or complex movements. PMC

6. Dystonic/tonic posturing. Fencing or asymmetric stiffening. Schn Health NSW

7. Vocalization. Shouts, cries, grunts, or profanities can occur. PMC

8. Partial awareness. Some individuals remember parts of the event; others have amnesia. NCBI

9. Brief aura. A rising feeling, fear, tingling, or chest sensation may precede movements. NCBI

10. Clustering. Many events in a single night or over several nights in a row. PMC

11. Daytime sleepiness. Fragmented sleep causes fatigue and trouble concentrating. PMC

12. Injury risk. Sudden movements can lead to falls, bruises, or bed partner injury. PMC

13. Psychosocial impact. Anxiety about sleeping and bed-sharing difficulties are common. PMC

14. Occasional daytime seizures. A minority also have daytime focal events. NCBI

15. Normal exam between seizures. Neurologic exam is often normal when awake. Schn Health NSW

---

Diagnostic tests

A) Physical exam (bedside assessment)

1. Standard neurological exam. Doctors check strength, reflexes, sensation, gait, and eye movements. Normal findings support a functional rather than degenerative process. Schn Health NSW

2. Sleep and seizure history. Detailed timing (first third of night, clustering), very short events, and stereotypy point to SHE over parasomnias. PMC

3. Witness/bed-partner report. Consistent descriptions of rapid, violent movements with minimal confusion after the event are red flags for ADSHE rather than parasomnia. Epilepsy Diagnosis

4. Injury screening. Look for bruises or bed damage; this helps risk assessment and safety planning. PMC

B) “Manual clinical tests (clinic-based, non-device procedures)

5. Structured sleep questionnaire & diary. Patterns of short, frequent, stereotyped events during NREM sleep suggest SHE. PMC

6. Parasomnia checklist. Longer (often >10 minutes), variable, and infrequent events with confused awakening and no recall favor parasomnia, not SHE. Epilepsy Diagnosis

7. Sleep hygiene & trigger review. Sleep deprivation and irregular schedules can unmask events; documenting this guides management and testing plans. PMC

8. Family pedigree mapping. An autosomal-dominant pattern across generations supports ADSHE and prioritizes genetic testing. NCBI

C) Laboratory & pathological tests

9. Targeted epilepsy gene panel. Includes CHRNA4, CHRNB2, CHRNA2, KCNT1, DEPDC5, NPRL2, NPRL3, and others. A positive result confirms a genetic cause. MedlinePlus+1

10. mTOR-pathway/GATOR1 analysis. Detects DEPDC5/NPRL2/NPRL3 variants; some positive families have subtle cortical dysplasia. MedlinePlus+1

11. KCNT1 functional annotation (specialized labs). Interprets likely pathogenic changes when clinical phenotype fits ADSHE with early onset. Taylor & Francis Online

12. General metabolic screen. While usually normal, checking electrolytes, glucose, and toxicology helps exclude mimics that worsen nocturnal events. PMC

D) Electrodiagnostic tests

13. Routine scalp EEG (awake/drowsy). Often normal between seizures; absence of epileptiform spikes does not rule out ADSHE. Schn Health NSW

14. Overnight video-EEG polysomnography (V-PSG). The gold standard: captures hypermotor seizures during NREM and links movements to ictal EEG change when visible. PMC

15. Sleep-deprived EEG / activation. Increases the chance of recording interictal abnormalities or provoking typical events safely in a monitored setting. PMC

16. High-density EEG or MEG (special centers). Improves source localization in MRI-negative cases to guide treatment planning, including surgery. PMC

E) Imaging tests

17. High-resolution epilepsy-protocol MRI. Many ADSHE cases are MRI-negative, but some show focal cortical dysplasia (often type II); imaging still matters for safety and planning. International League Against Epilepsy

18. Ictal/interictal SPECT. Perfusion changes can help localize a deep or frontal focus when scalp EEG is nonlocalizing. PMC

19. FDG-PET. Interictal hypometabolism in the frontal region may support the diagnosis and guide invasive monitoring if surgery is considered. PMC

20. Combined EEG-fMRI (research/specialized). Detects hemodynamic changes time-locked to epileptiform activity to refine the seizure network map. PMC

Non-pharmacological treatments

1. Sleep hygiene program. Purpose: stabilize sleep to raise seizure threshold. Mechanism: consistent bed/wake times reduce sleep-deprivation–induced cortical excitability. PMC+1

2. Treat sleep disorders (e.g., sleep apnea). Purpose: remove nocturnal triggers. Mechanism: reducing arousals and hypoxia lowers nocturnal seizure risk. Sleep Foundation

3. Stress-reduction skills (breathing, CBT-based tools). Purpose: reduce stress-triggered seizures. Mechanism: dampens stress hormone effects on neuronal excitability. CDC

4. Seizure-trigger diary & education. Purpose: identify patterns (missed meds, menses, lights). Mechanism: avoiding triggers lowers risk. CDC+1

5. Safety planning at night (monitor, padded bed edges if needed). Purpose: reduce injury during nocturnal events. Mechanism: environmental modifications. CDC

6. Regular physical activity. Purpose: mood/sleep gains; possible seizure benefit. Mechanism: improves sleep consolidation and reduces stress. World Health Organization

7. Caffeine/alcohol moderation. Purpose: avoid sleep fragmentation and acute triggers. Mechanism: alcohol binges increase seizure risk; caffeine late at night worsens sleep. Epilepsy Foundation

8. Consistent medication routines & pill organizers. Purpose: prevent missed doses (a common trigger). Mechanism: maintains steady drug levels. CDC

9. Education for bed partner/family. Purpose: early recognition, filming events, first-aid. Mechanism: better data and safer responses. Epilepsy Foundation

10. Blue-light management in evenings. Purpose: improve sleep onset. Mechanism: supports melatonin rhythm, aiding seizure threshold. Sleep Medicine Resources

11. Weight management if needed. Purpose: lowers OSA risk. Mechanism: reduces arousals. Sleep Foundation

12. Mind-body practices (guided relaxation). Purpose: stress and sleep improvement. Mechanism: autonomic balancing. CDC

13. Work/school adjustments for adequate sleep. Purpose: protect regular sleep opportunity. Mechanism: prevents deprivation spikes. PMC

14. Photostimulation avoidance if photosensitive. Purpose: minimize reflex triggers. Mechanism: reduces cortical over-activation. CDC

15. Temperature regulation at night. Purpose: prevent arousals. Mechanism: stable thermoregulation supports NREM. Sleep Medicine Resources

16. Seizure-alert devices (select cases). Purpose: detect events for help/supervision. Mechanism: motion/HR algorithms. Health

17. Education on SUDEP risk reduction. Purpose: maximize seizure control and supervision. Mechanism: fewer GTCs/nighttime seizures reduces SUDEP risk. Epilepsy Foundation+1

18. Diet therapy program (ketogenic or modified Atkins). Purpose: reduce seizures in drug-resistant cases. Mechanism: ketone metabolism alters excitability. Cochrane Library+1

19. Melatonin (discuss with clinician). Purpose: aid sleep; mixed seizure data. Mechanism: circadian stabilization; anticonvulsant signals are inconclusive. PMC+1

20. Patient support groups. Purpose: education, adherence, coping. Mechanism: peer support improves self-management. CDC

---

Drug treatments

1. Carbamazepine (Tegretol/Carbatrol/Equetro) – sodium-channel blocker.
   Typical adult total 800–1200 mg/day divided; start low and titrate. Purpose: reduce focal nocturnal seizures. Mechanism: stabilizes inactivated Na⁺ channels to reduce repetitive firing. Notable risks: rash (rare SJS/TEN; HLA testing in some ancestries), hyponatremia, leukopenia, drug interactions. FDA Access Data+2FDA Access Data+2

2. Oxcarbazepine (Trileptal) – sodium-channel modulator.
   Adults often 1200–2400 mg/day in 2 doses; start 300 mg BID and titrate. Purpose: alternative to carbamazepine with fewer interactions. Risks: hyponatremia, dizziness, rash. FDA Access Data+1

3. Topiramate (Topamax) – multiple mechanisms (Na⁺ channels, GABA-A, AMPA/kainate).
   Common target 200–400 mg/day divided; titrate slowly. Risks: cognitive slowing, paresthesias, kidney stones, metabolic acidosis; bone density concerns in pediatrics. FDA Access Data+1

4. Lamotrigine (Lamictal) – Na⁺ channel + glutamate release modulation.
   Slow titration to 200–400 mg/day (varies by co-meds). Purpose: focal control with favorable cognition. Boxed warning: serious rash (SJS/TEN). FDA Access Data+1

5. Levetiracetam (Keppra) – SV2A modulator.
   Common 1000–3000 mg/day divided. Purpose: add-on for focal seizures. Risks: irritability/mood changes; adjust in renal impairment. FDA Access Data

6. Lacosamide (Vimpat) – slow inactivation of Na⁺ channels.
   Usual 200–400 mg/day divided; IV option. Risks: PR-interval prolongation, dizziness; controlled substance. FDA Access Data+1

7. Perampanel (Fycompa) – AMPA receptor negative modulator.
   Bedtime dosing starting 2 mg; titrate by 2 mg weekly; watch aggression/irritability (boxed-warning language). FDA Access Data+1

8. Brivaracetam (Briviact) – SV2A ligand.
   50–200 mg/day divided; oral or IV at same total daily dose; label recently updated with safety changes. FDA Access Data+1

9. Cenobamate (Xcopri) – Na⁺ modulation + GABA-A modulation.
   Start 12.5 mg/day and titrate over weeks to 200 mg/day; max 400 mg/day; DRESS risk requires slow titration. FDA Access Data+1

10. Clobazam (Onfi) – benzodiazepine (GABA-A).
    Common 10–40 mg/day; sedation and tolerance possible; schedule IV. FDA Access Data+1

11. Valproate/Valproic acid (Depakote/Depakene).
    Broad-spectrum; typical 10–60 mg/kg/day; avoid in pregnancy when possible (teratogenic, neurodevelopmental risk); monitor liver, ammonia. FDA Access Data+1

12. Zonisamide (Zonegran) – Na⁺/T-type Ca²⁺ effects (label not shown above).
    Often 200–400 mg/day once-daily; risks include kidney stones, weight loss, sulfonamide rash (use FDA label in practice). (Label available on FDA site.) World Health Organization

13. Rufinamide (Banzel).
    Adjunct for focal in some cases; food increases absorption; watch QT-shortening. (See FDA labeling for precise dosing.) World Health Organization

14. Gabapentin (Neurontin).
    Less commonly used as sole ASM for ADSHE; sedation/dizziness; renal dosing. (FDA label supports focal add-on indications historically.) World Health Organization

15. Pregabalin (Lyrica).
    Adjunctive for focal; sedation/weight gain; controlled substance. (See FDA label for focal seizures.) World Health Organization

16. Phenobarbital.
    Effective but sedating/cognitive effects; enzyme inducer; consider in resource-limited settings. (FDA labeling available.) World Health Organization

17. Phenytoin.
    Older Na⁺ blocker; narrow therapeutic index; interactions/side effects limit long-term use. (FDA label supports dosing/risks.) World Health Organization

18. Clonazepam.
    Benzodiazepine; useful as bridge; tolerance/sedation limit chronic use. (FDA label.) World Health Organization

19. Cannabidiol (Epidiolex).
    Labeled for LGS/Dravet/TSC; not ADSHE-specific but sometimes tried off-label in refractory focal epilepsies; monitor LFTs and interactions (esp. clobazam, valproate). FDA Access Data+1

20. Quinidine (KCNT1-specific precision attempts).
    Not FDA-approved for epilepsy; occasionally tried to block KCNT1 channel gain-of-function; overall results inconsistent in reviews—use only in expert centers. PubMed+1

⚠️ Important: Doses vary by age, kidney/liver function, pregnancy, drug interactions, and formulation. Always use the current FDA label for exact instructions and warnings and adjust with your neurologist. FDA Access Data

---

Dietary molecular supplements

1. Omega-3 fatty acids. May help general brain health; seizure data mixed; typical 1–2 g/day EPA+DHA with meals. World Health Organization

2. Vitamin D. Correct deficiency to support bone health (many ASMs lower bone mineral density); dose per labs. FDA Access Data

3. Magnesium. If deficient, repletion can aid sleep and neuromuscular function; diarrhea is dose-limiting. World Health Organization

4. Melatonin. Helps sleep; seizure effect uncertain; typical 1–5 mg 30–60 min before bed. PMC+1

5. B-complex (esp. B6 in rare infantile disorders). Routine high-dose B6 isn’t indicated in ADSHE; correct deficiencies only. World Health Organization

6. Carnitine. Consider only with valproate-related deficiency or specific indications. FDA Access Data

7. Selenium/zinc (deficiency-based). Replace if low; no robust ADSHE-specific data. World Health Organization

8. CoQ10. Antioxidant rationale; limited epilepsy evidence. World Health Organization

9. Taurine. GABAergic hypothesis; clinical evidence is limited. World Health Organization

10. Probiotics (sleep/gut axis). Early data for sleep quality; seizure effect unknown. World Health Organization

Note: Supplements can interact with ASMs. Discuss all products with your clinician and do not replace prescribed medicines. CDC

---

Immunity-booster/regenerative/stem-cell drugs

There are no FDA-approved immune-booster or stem-cell drugs for treating ADSHE or any epilepsy syndrome. Using them outside clinical trials is not evidence-based and may be risky. If you’re exploring cutting-edge options, ask about registered clinical trials or device/surgical therapies with established evidence instead. World Health Organization

---

Procedure options

1. Vagus Nerve Stimulation (VNS). Implanted pulse generator stimulates the vagus nerve to reduce seizures; evidence supports benefit in drug-resistant focal epilepsy. Cochrane+1

2. Responsive Neurostimulation (RNS). A cranial device detects and interrupts seizures at their source; long-term studies show median ~75% reduction over years in focal epilepsy. American Academy of Neurology+1

3. Deep Brain Stimulation—Anterior Nucleus (DBS-ANT). Thalamic stimulation can reduce focal seizures; SANTE data show increasing benefit over time. PMC+1

4. Resective surgery (frontal focus). If one focus is proven (often via stereo-EEG), removing it can lead to seizure freedom or major reduction in carefully selected cases. Lippincott Journals+1

5. Laser interstitial thermal therapy (LITT). MRI-guided thermal ablation for select focal epilepsies—less invasive, with growing outcome data. PMC

---

Prevention tips

Keep a regular sleep schedule, take medicines exactly as prescribed, manage stress, limit alcohol, treat sleep apnea, exercise regularly, keep a seizure diary, avoid personal triggers (including light/sound where relevant), maintain healthy weight, and review safety plans (night-time supervision/devices as appropriate). These steps lower seizure risk and improve quality of life. CDC+2PMC+2

---

When to see a doctor

See your neurologist if seizures change in pattern, increase in number, injuries happen at night, side effects appear, pregnancy is planned, or mood/memory problems grow. Call emergency services for any seizure lasting >5 minutes, repeated seizures without recovery, serious injury, breathing trouble, or if a first-ever seizure occurs. Regular reviews also help reduce SUDEP risk by improving control. CDC+1

---

What to eat (and what to avoid)

Aim for a balanced, sleep-friendly diet: regular mealtimes, fiber-rich foods, lean protein, and healthy fats. If you and your clinician choose ketogenic or modified Atkins therapy, follow a supervised plan to ensure adequate nutrients and safe ketosis. Limit heavy late-night meals, high-sugar spikes, binge alcohol, and energy drinks close to bedtime—these can disturb sleep or interact with medicines. Cochrane Library+2PMC+2

---

FAQs

1) Is ADSHE rare?
Yes. It’s an uncommon familial epilepsy with sleep-related motor seizures; exact prevalence is low, and many families carry gene variants affecting neuronal excitability. NCBI+1

2) Why mostly at night?
Sleep transitions (especially NREM) change brain network balance, lowering seizure threshold in ADSHE circuits. Wiley Online Library

3) Is it always the frontal lobe?
Often frontal semiology, but modern definitions focus on sleep-related motor features; onset zone can vary. Wiley Online Library

4) What is the inheritance pattern?
Autosomal dominant: one altered gene copy can cause disease; penetrance varies. NCBI

5) Which genes are common?
nAChR subunits (CHRNA2, CHRNA4, CHRNB2) and others like KCNT1, DEPDC5/NPRL2/3. MedlinePlus+2MedlinePlus+2

6) Do most people respond to medicine?
Many improve on carbamazepine/oxcarbazepine; some need add-ons or device/surgery. Pedneur

7) Are diet therapies legit?
Yes for drug-resistant epilepsy in general (ketogenic/MAD), with specialist supervision. Cochrane Library+1

8) Is CBD (Epidiolex) approved for ADSHE?
No—approved for LGS, Dravet, and TSC; sometimes considered off-label in refractory focal epilepsy. FDA Access Data

9) What about quinidine for KCNT1?
Evidence is mixed; not standard and not FDA-approved for epilepsy—expert center only. PubMed

10) Can improving sleep really help?
Yes. Even small amounts of deprivation can raise seizure risk the next day. PMC

11) Is alcohol a problem?
Yes—especially heavy use; it disrupts sleep and can trigger seizures. Epilepsy Foundation

12) What if medicines fail?
Discuss VNS, RNS, DBS-ANT, focused resection, or LITT at a comprehensive epilepsy center. Cochrane+2American Academy of Neurology+2

13) What is SUDEP and how do I reduce risk?
Sudden unexpected death in epilepsy; best prevention is strong seizure control and night-time safety planning. Epilepsy Foundation+1

14) Can children outgrow it?
Some improve with age; others need ongoing therapy—follow-up is key. NCBI

15) Where to find trustworthy info?
ILAE, MedlinePlus Genetics, Epilepsy Foundation, and FDA drug labels. International League Against Epilepsy+2MedlinePlus

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 03, 2025.

PDF Documents For This Disease Condition References